UAEM - Licensing and patenting practices of UK research institutions 2019-2020

Sarai Keestra made this Freedom of Information request to University of Manchester

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Manchester,

We have previously sent FOI requests asking for information about the licensing practices of UK universities. This was concerning the time period 18th October 2018 to 18th October 2019. We are now looking to update the information for the following year, 19th October 2019 to 19th October 2020.

The updated request is listed below:
For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...
Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit
❏ Published an article, guidance, or other literature on access licensing practices
❏ Formally presented on access licensing practices at an academic or professional event, or at another university
❏ Informally shared or discussed access licensing practices with administrators at other universities
❏ Other
❏ None
(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

MTRS FOIA, University of Manchester

Dear Sarai,

I am writing to acknowledge your request under the Freedom of Information Act 2000 received by The University of Manchester yesterday, our reference as per the subject line.

The University will respond to your request within 20 working days.

NB Due to the current situation with the Covid-19 virus and the University’s response to it, there may be a delay in receiving your response at this time.

Kind regards

Sharon

Sharon Glen | Information Officer | Information Governance Office | Directorate of Compliance and Risk |Professional Services | G7 Christie Building | The University of Manchester | Oxford Road | Manchester | M13 9PL | Tel +44(0) 161 306 7549| www.manchester.ac.uk

We are all responsible for protecting personal data held by the University, including who we share that data with. Stop and think before you send your email.  For further guidance see: www.dataprotection.manchester.ac.uk

show quoted sections

MTRS FOIA, University of Manchester

4 Attachments

Dear Sarai,

 

Thank you for your request for information received by The University of
Manchester on 10 November 2020 which was as follows:

 

Q1. Has the university committed to licensing its medical discoveries in
ways that promote access and affordability in Low- and Middle- Income
Countries? If yes, please provide a link or PDF to the relevant policy
document.

 

Q2. Please provide an Excel spreadsheet with headings as displayed below
with all the health technologies LICENSED by the university in the period
19th October 2019 to 19th October 2020 AND specify which countries they
were licensed in AND specify whether they are exclusive or non-exclusive
licenses.

 

Health Technology Licensed | Country of Licensing | Type of License
(Exclusive or Non-Exclusive)

 

Q3. Please provide a list of patents granted to your organization in the
period 19th October 2019 to 19th October 2020, listed by patent family,
indicating countries/regions in which the patent has been granted.

 

Q4. In the period 19th October 2019 to 19th October 2020, has the
university shared its best practices for promoting access to medicines
through non-exclusive licensing by carrying out any of the following
activities?

 

❏ Contributed sample clauses to the AUTM Global Health Toolkit

 

❏ Published an article, guidance, or other literature on access licensing
practices

 

❏ Formally presented on access licensing practices at an academic or
professional event, or at another university

 

❏ Informally shared or discussed access licensing practices with
administrators at other universities

 

❏ Other

 

❏ None

 

(Tick as appropriate)

 

Q5. What actions has the technology transfer office (TTO) undertaken in
the period 19th October 2019 to 19th October 2020 to improve access to the
technologies they license in low-and middle-income settings?

 

The University has now considered your request and our response can be
found below.

 

1.       See UoM IP Policy – attached.

2.       See attached “UoM FOI Request_licences 020-619”.

3.       See attached “UoM FOI Request_granted patents 020-619”. NB as per
your other questions we have interpreted this as health technologies only.

4.       None.

5.       None.

 

I trust this information is of use to you.

 

Kind regards

 

Sharon

 

Sharon Glen | Information Officer | Information Governance Office |
Directorate of Compliance and Risk |Professional Services | G7 Christie
Building | The University of Manchester | Oxford Road | Manchester | M13
9PL | Tel +44(0) 161 306 7549| [1]www.manchester.ac.uk

[2]data_matters_logo2-(3)

We are all responsible for protecting personal data held by the
University, including who we share that data with. Stop and think before
you send your email.  For further guidance see:
[3]www.dataprotection.manchester.ac.uk

 

References

Visible links
1. http://www.manchester.ac.uk/
3. http://www.dataprotection.manchester.ac....